{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:03:50Z","timestamp":1791187430705,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Our study aims to assess the effectiveness and safety profile of Disitamab Vedotin (DV, RC48-ADC), an innovative humanized anti-HER2 antibody conjugated with tubulin-disrupting antimitotic drug monomethyl auristatin E (MMAE) via a cleavable peptide linker. This treatment combined immune checkpoint inhibitors as part of the bladder sparing approach for selected patients suffering from locally and locally advanced bladder urothelial carcinoma.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods:<\/jats:bold>\n                    We conducted a two-center, real-world study involving locally advanced urothelial carcinoma (UC) patients. Patients were classified based on HER2 expression (IHC 3+\/2+\/1+) or lack of HER2 expression (IHC 0). The primary endpoint was the objective response rate (ORR), assessed by the investigator following the criteria of RECIST V1.1. Secondary endpoints encompassed the pathological complete response rate (pCR), pathological partial response rate (pPR), and pathological stable disease (pSD), along with recurrence-free survival (RFS), the pathological downstaging rate, and the safety profile of the treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In this study, nine patients were enrolled, with a median follow-up duration of 12.0\u00a0months. The overall confirmed ORR was 88.9%, Five patients achieved a complete response (CR), and three patients achieved a partial response (PR). The radiological complete response (rCR) aligned perfectly with pCR. The median radiological progression-free survival (rPFS) spanned 12.0\u00a0months (range from 8.0 to 17.0\u00a0months). One patient diagnosed with disease progression (PD) underwent a radical cystectomy. The pathological stage evolved from T2N0M0 to T3aN2M0, followed by adjuvant chemotherapy with a gemcitabine-cisplatin (GC) combination radiotherapy. At the 9-month follow-up, neither recurrence nor metastasis was observed. The rate and intensity of complications were manageable among these patients, with no evidence of grade 4 and 5 adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The combination of DV and PD-1 demonstrated considerable activity in the objective response rate (ORR) in patients with HER2 IHC 0\/1+\/2+\/3+ muscle-invasive bladder cancer (MIBC), along with the longest reported median radiological progression-free survival (rPFS) to date. With an extended duration of treatment, the safety profile of DV plus PD-1 was also confirmed to be manageable.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1230395","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T08:46:21Z","timestamp":1692002781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center\u2019s real-world study"],"prefix":"10.3389","volume":"14","author":[{"given":"Yongbao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruochen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody,in patients with refractory metastatic urothelial carcinoma: results from a multicenter,phase ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B2","volume-title":"Pembrolizumab in combination with gemcitabine andconcurrent hypofractionated radiation therapy asbladder sparing treatment for muscle-invasiveurothelial cancer of the bladder: A multicenter phase 2 trial","author":"Balar","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1200\/jco.2021.39.15_suppl.4532","article-title":"Pembrolizumab (pembro) versus investigator\u2019s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial","volume":"39","author":"Bellmunt","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1002\/cncr.29047","article-title":"Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: A review of SEER data","volume":"120","author":"Charlton","year":"2014","journal-title":"Cancer"},{"key":"B6","first-page":"1957","article-title":"Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder","volume":"7","author":"Chow","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"B7","volume-title":"GU14-188: Phase 1b\/2 neoadjuvant pembrolizumab and chemotherapy for locally advanced urothelial cancer: Final results of the cisplatin-eligible cohort (NCT02365766)","author":"Christopher","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation.The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D\u2019Amico","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur. Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur. Urol."},{"key":"B12","volume-title":"Phase ll trial of durvalumab plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladdercancer treated with a selective bladder preservation approach:IMMUNOPRESERVE-SOGUC trial","author":"Garcia del Muro","year":"2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B14","article-title":"Results from BLASST-1(Bladder Cancer Signal Seeking Trial) ofnivolumab, gemcitabine, and cisplatin in muscle invasive bladdercancer patients undergoing cystectomy","author":"Guptal","year":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1172\/JCI126598","article-title":"U3\u20131402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation","volume":"130","author":"Haratani","year":"2020","journal-title":"J. Clin. Investig."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e16616","article-title":"The efficacy and safety of RC48 in patients with non-muscle invasive bladder cancer","author":"Hu","year":"2023","journal-title":"SIU Around world Montr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e15157","DOI":"10.1016\/j.heliyon.2023.e15157","article-title":"Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report","volume":"9","author":"Huang","year":"2023","journal-title":"HELIYON"},{"key":"B19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","article-title":"A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+tumors in hPD-1 transgenic mouse model and contributes immune memory formation","volume":"191","author":"Huang","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"","journal-title":"N. Engl. J. Med"},{"key":"B22","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3892\/ijo.21.5.981","article-title":"Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome","volume":"21","author":"Kruger","year":"2002","journal-title":"Int. J. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladderpreserving combined-modality therapy: A pooled analysis of radiation therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-Arm,Phase II study","volume":"36","author":"Necchi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0360-3016(97)00579-8","article-title":"Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer","volume":"40","author":"Sauer","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-21-2210","article-title":"Safety, efficacy and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: results from a multicenter phase II trial POLARIS-03","volume":"28","author":"Sheng","year":"","journal-title":"Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody\u2013drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"","journal-title":"Clin. Cancer Res."},{"key":"B31","volume-title":"Preliminary results of a phase Ib\/ll combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma(La\/mUC)","author":"Sheng","year":"2022"},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","article-title":"Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two nordic studies","volume":"45","author":"Sherif","year":"2004","journal-title":"Eur. Urol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fj.201700740R","article-title":"Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy","volume":"32","author":"Wang","year":"2018","journal-title":"FASEB J."},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.10.170","volume-title":"A multi-center phase Ib\/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced MIBC","author":"Wen","year":"2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.juro.2011.06.004","article-title":"Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: A comparative study","volume":"186","author":"Zehnder","year":"2011","journal-title":"J. Urol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1230395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T08:46:37Z","timestamp":1692002797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1230395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":37,"alternative-id":["10.3389\/fphar.2023.1230395"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1230395","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"article-number":"1230395"}}